DXCM vs. MMM, BDX, RMD, BAX, PODD, TFX, NVCR, BSX, SYK, and WST
Should you be buying DexCom stock or one of its competitors? The main competitors of DexCom include 3M (MMM), Becton, Dickinson and Company (BDX), ResMed (RMD), Baxter International (BAX), Insulet (PODD), Teleflex (TFX), NovoCure (NVCR), Boston Scientific (BSX), Stryker (SYK), and West Pharmaceutical Services (WST). These companies are all part of the "surgical & medical instruments" industry.
DexCom (NASDAQ:DXCM) and 3M (NYSE:MMM) are both large-cap medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their media sentiment, analyst recommendations, institutional ownership, dividends, community ranking, earnings, risk, valuation and profitability.
DexCom has a beta of 1.23, suggesting that its share price is 23% more volatile than the S&P 500. Comparatively, 3M has a beta of 1, suggesting that its share price has a similar volatility profile to the S&P 500.
In the previous week, 3M had 21 more articles in the media than DexCom. MarketBeat recorded 37 mentions for 3M and 16 mentions for DexCom. DexCom's average media sentiment score of 1.09 beat 3M's score of 0.42 indicating that DexCom is being referred to more favorably in the media.
DexCom received 66 more outperform votes than 3M when rated by MarketBeat users. Likewise, 71.97% of users gave DexCom an outperform vote while only 59.45% of users gave 3M an outperform vote.
97.8% of DexCom shares are owned by institutional investors. Comparatively, 65.3% of 3M shares are owned by institutional investors. 0.3% of DexCom shares are owned by company insiders. Comparatively, 0.3% of 3M shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.
DexCom currently has a consensus target price of $141.67, suggesting a potential upside of 7.85%. 3M has a consensus target price of $107.55, suggesting a potential upside of 2.17%. Given DexCom's stronger consensus rating and higher probable upside, equities analysts clearly believe DexCom is more favorable than 3M.
DexCom has a net margin of 16.82% compared to 3M's net margin of -21.57%. 3M's return on equity of 95.80% beat DexCom's return on equity.
DexCom has higher earnings, but lower revenue than 3M. 3M is trading at a lower price-to-earnings ratio than DexCom, indicating that it is currently the more affordable of the two stocks.
Summary
DexCom beats 3M on 14 of the 19 factors compared between the two stocks.
Get DexCom News Delivered to You Automatically
Sign up to receive the latest news and ratings for DXCM and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding DXCM and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Related Companies and Tools
